# Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

> **NCT01937117** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 88 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **PROCEDURE:** Positron emission tomography (PET)
- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab

## Key facts

- **NCT ID:** NCT01937117
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-01-30
- **Primary completion:** 2018-03-20
- **Final completion:** 2026-06
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2025-07-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01937117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01937117, "Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01937117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*